Analgin, 500 mg/ml 2 ml 10 pcs

Panalgin non-selectively blocks cyclooxygenase and reduces formation of prostaglandins from arachidonic acid, interferes with conduction of pain extra- and proprioceptive impulses.

The analgin has a weak anti-inflammatory effect, resulting in little effect on the water-salt metabolism (sodium and water retention) and the mucous membrane of the gastrointestinal tract. It has antispasmodic effect on smooth muscles of urinary and biliary tracts. Action develops 20-40 minutes after oral administration.

Pharmacokinetics

After intravenous administration, the elimination half-life for sodium metamizole is 14 minutes.

Approximately 96% is excreted in the urine as metabolites. Binding of the active metabolite with blood plasma proteins is 50-60%. Primarily excreted by the kidneys.

Indications

• Pain syndrome (mild to moderate severity): including headache, migraine, toothache, neuralgia, myalgia, radicular syndrome, algodysmenorrhea; with renal, hepatic and biliary colic (in combination with antispasmodics).
• Analgin may be used to reduce pain after surgical and diagnostic interventions.
• Elevated body temperature in “colds” and other infectious and inflammatory diseases. The appropriateness of the drug is decided in each case depending on the severity, nature and tolerability of the fever.

Active ingredient

Sodium metamizole

Composition

1 ml of solution for injection contains:

the active ingredient:

metamizole sodium (analgin) 500 mg,

excipients:

water for injection to 1 ml.

.

How to take, the dosage

Adults and adolescents 15 years and older: as a single dose, 1-2 ml of Analgin 500 mg/mL solution or 2-4 ml of Analgin 250 mg/mL solution (intramuscularly or intravenously), the daily dose can be up to 4-8 ml of 500 mg/mL injection solution or 250 mg/mL injection solution (maximum 2 g), divided into 2-3 doses. The maximum single dose may be 1 g (2 ml of 500 mg/ml solution or 4 ml of 250 mg/ml solution).

In children and newborns: Analgin should not be administered to newborns under 3 months of age or with a body weight of less than 5 kg.

In children, Analgin is prescribed in a dose of 5-10 mg per 1 kg of body weight (0.1-0.2 ml of 500 mg/ml solution or 0.2-0.4 ml of 250 mg/ml solution).

A single dose may be administered up to 2-3 times a day.

Heating the solution to body temperature is recommended before administering.

For children aged 3-12 months, the administration is by intramuscular injection only! (child’s body weight from 5 to 9 kg).

If the drug is administered too quickly, a critical drop in blood pressure and shock may occur. Intravenous administration should be carried out slowly (infusion rate of not more than 1 ml (500 mg of sodium metamizole per minute)) in the supine position, while monitoring blood pressure, pulse and respiratory rate.

Because there is concern that the drop in blood pressure of non-allergic genesis is dose-dependent, amounts of Analgin solution greater than 2 ml (1 g) should be administered with extreme caution.

Interaction

The concomitant use of Analgin with other non-narcotic analgesics may lead to a mutual increase in toxic effects.

Tricyclic antidepressants, oral contraceptives and allopurinol impair the metabolism of sodium metamizole in the liver and increase its toxicity.

Barbiturates and phenylbutazone weaken the effects of Analgin.

Analgin increases the effects of alcohol-containing drinks.

Rentgen contrast drugs, colloidal blood substitutes and penicillin should not be used during treatment with sodium metamizole.

Sodium metamizole displaces oral hypoglycemic drugs, indirect anticoagulants, glucocorticosteroids and indomethacin from binding to protein and increases their activity.

The concomitant use of Analgin with cyclosporine reduces the blood levels of the latter.

Tiamazole and sarcolysin increase the risk of leukopenia.

The effect is increased by codeine, H2-histamine receptor blockers, propranololol (slows inactivation).

Sedatives and tranquilizers increase the analgesic effect of Analgin.

Myelotoxic drugs increase the manifestation of hematotoxicity of the drug.

Because of the high likelihood of pharmaceutical incompatibility, methamisole should not be mixed with other medicinal products in the same syringe.

Special Instructions

In patients suffering from bronchial asthma and pollinosis, hypersensitivity reactions may develop.

When prolonged use (more than 7 days) it is necessary to monitor the peripheral blood picture. During sodium metamizole administration agranulocytosis may develop, therefore in case of unexplained fever, chills, sore throat, difficulty in swallowing, stomatitis, erosive oral ulcers, vaginitis or proctitis the drug should be immediately discontinued.

Do not use for acute abdominal pain (until the cause is known).

To reduce the risk of gastrointestinal adverse events, the lowest effective dose should be used for the shortest possible course.

When treating patients receiving cytostatic agents, sodium metamizole should only be taken under medical supervision.

In intramuscular administration a long needle must be used.

Contraindications

• high sensitivity to pyrazolone derivatives (propiphenazone, phenazone or phenylbutazone);
• bronchial asthma induced by taking acetylsalicylic acid, salicylates or other non-steroidal anti-inflammatory drugs (NSAIDs);
• bronchoobstruction, rhinitis, urticaria, triggered by taking acetylsalicylic acid or other NSAIDs (incl.ч.
• Hematopoiesis inhibition (agranulocytosis, cytostatic or infectious neutropenia);
• explicit hepatic or renal impairment;
• hepatic porphyria;
• confirmed hyperkalemia, erosive-ulcerative changes of the mucous membrane of the stomach and duodenum, active gastrointestinal bleeding, inflammatory bowel disease, anemia, leukopenia;
• hereditary hemolytic anemia associated with glucose-6-phosphate dehydrogenase deficiency
• pregnancy (especially in the first trimester and last 6 weeks), lactation
• infant age (less than 3 months with a body weight <5 kg).

.

Side effects

Urinary system disorders: impaired renal function, oliguria, anuria, proteinuria, very rare development of acute interstitial nephritis, staining of urine red (due to excretion of the metabolite – rubazonic acid).

Allergic reactions: urticaria, including conjunctivitis and mucous membranes of the nasopharynx, Quincke’s edema; in rare cases – erythema malignant exudative (Stevens-Johnson syndrome), anaphylactic shock, toxic epidermal necrolysis (Lyell syndrome), bronchospastic syndrome (not only with tendency to bronchospasm).

Hematopoietic disorders: leukopenia, rarely agranulocytosis and thrombocytopenia of immune origin.

Others: possible decrease in blood pressure, impaired heart rhythm.

Local reactions: when administered intramuscularly, infiltrates may occur at the site of injection.

Overdose

In case of overdose, a physician should be consulted. The following symptoms may occur: nausea, vomiting, stomach pain, oliguria, hypothermia, decreased blood pressure, tachycardia, shortness of breath, tinnitus, drowsiness, delirium, impaired consciousness, acute agranulocytosis, hemorrhagic syndrome, acute renal and/or liver failure, seizures, paralysis of respiratory muscles.

Treatment: symptomatic. There is no specific antidote for sodium metamizole. In the setting of the hospital – forced diuresis, hemodialysis, in the development of a convulsive syndrome – intravenous administration of diazepam and fast-acting barbiturates.

.

Similarities

Analgin Ultra, Baralgin M, Analgin, Analgin Renewal